March 12 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q4 LOSS PER SHARE $0.60.Q4 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.EXPECTS TO INITIATE STUDY MID-YEAR 2018 TO SUPPORT AN NDA FOR ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS - BELIEVES CASH,CASH EQUIVALENT POSITION AS OF DEC 31, 2017 IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $62.5 MILLION AS OF DEC 31, 2017 SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS WELL INTO 2019.
Full Article
March 5 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING.ZYNERBA - EXPECTS TO INITIATE SINGLE PIVOTAL STUDY MID-YEAR 2018 TO SUPPORT NDA FOR ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS SAYS FDA & CO ARE IN AGREEMENT OVER PRIMARY & KEY SECONDARY ENDPOINTS FOR ZYN002 IN FRAGILE X SYNDROME.
Full Article
Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE.ZYNERBA PHARMACEUTICALS INC - PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018.ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS.ZYNERBA - IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES.ZYNERBA PHARMACEUTICALS INC - PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019.
Full Article
Nov 14 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights.Q3 loss per share $0.63.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Zynerba Pharmaceuticals - believes cash and cash equivalent position as of September 30, 2017 is sufficient to develop five phase 3-ready programs.Zynerba Pharmaceuticals Inc - believes that cash and cash equivalent position of as of September 30, 2017 is sufficient to fund operations into 2019.
Full Article
Sept 28 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome.Zynerba Pharmaceuticals Inc - ZYN002 successfully met primary endpoint and showed clinically meaningful improvements.Zynerba Pharmaceuticals Inc - ZYN002 successfully met primary endpoint and showed clinically meaningful improvements.Zynerba Pharmaceuticals Inc - study successfully met its primary endpoint,.Zynerba Pharmaceuticals Inc says ZYN002 was well tolerated in Fragile X patients.Zynerba Pharmaceuticals Inc - zynerba anticipates that it will meet with U.S. Food and Drug Administration in first half of 2018.Zynerba Pharmaceuticals - two patients discontinued due to worsening of pre-existing eczema, four other patients experienced an adverse event in trial.Zynerba Pharmaceuticals Inc - anticipates moving into pivotal Phase 2/3 program in pediatric and adolescent patients with FXS in 2018.
Full Article
Aug 14 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis.Study did not meet its primary endpoint.Says trend toward statistical significance was observed in other secondary endpoints.Statistically significant results were achieved for a number of secondary endpoints in trial.Says statistically significant results were achieved for a number of secondary endpoints.Top line data from ZYN002 in its exploratory phase 2 FAB-C study are expected by end of September 2017.In study, ZYN002 shown to be very well tolerated & safety profile was consistent with previously released data from trials.Twelve (5.6%) patients that discontinued due to adverse events on ZYN002 and 8 (7.5%) that discontinued due to adverse events on placebo.
Full Article
Aug 7 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures.Zynerba - ZYN002 did not demonstrate a statistically significant reduction of focal seizures during treatment period.Zynerba Pharmaceuticals Inc - star 1 trial did not meet its primary endpoint.Zynerba Pharmaceuticals Inc - will present top-line data from ZYN002 stop trial in osteoarthritis soon.Zynerba Pharmaceuticals Inc - will present top-line data from Fab-C study in fragile X syndrome by end of September.Zynerba - patients on low dose of ZYN002 achieved 18.4% median reduction in focal seizures during treatment period versus baseline.Zynerba Pharmaceuticals Inc - none of secondary endpoints showed statistically significant differences between ZYN002 and placebo.
Full Article
Aug 1 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals reports second quarter 2017 financial results and operational highlights.Q2 loss per share $0.64.Q2 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.Zynerba expects to announce top-line results from Star 1 trial soon, followed by top-line data from stop trial later this month.Remains on track to report top-line results from fab-c fragile x study in September.
Full Article
June 8 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome.
Full Article
May 9 (Reuters) - Zynerba Pharmaceuticals Inc : :Zynerba Pharmaceuticals reports first quarter 2017 financial results and operational highlights.Q1 loss per share $0.60.Q1 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Zynerba Pharmaceuticals Inc - believes that current cash position of $77.5 million is sufficient to fund operations and capital requirements into 2019.
Full Article
Earnings vs. 
Estimates